Avicenna.AI | AI Radiology

Category: Press Release

Avicenna.AI Partners With Canon Medical on AI Stroke Detection

Paris, FRANCE – November 10, 2020 – Medical imaging AI specialist Avicenna.AI today announced a partnership with Canon Medical Systems Corporation to deliver a fully integrated stroke detection AI solution for Canon’s Automation Platform.
With this partnership, Avicenna provides Canon with its FDA-approved CINA Head triage AI solution for neurovascular emergencies, which detects two of the leading causes of stroke – intracranial hemorrhage (ICH) and large vessel occlusion (LVO) – from CT-scan imaging.
Using a combination of deep learning and machine learning technologies, CINA Head automatically detects and prioritizes acute ICH and LVO cases within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow.
CINA’s ICH detection capability was validated using data from 814 cases conducted at more than 250 imaging centers across the United States, with 96% accuracy, 91.4% sensitivity and 97.5% specificity. The product’s LVO detection capability was validated based on 476 cases, with 97.7% accuracy 97.9% sensitivity and 97.6% specificity.
Toshiki Kato, General Manager of Healthcare IT, Canon Medical Systems, said, “Our partnership with Avicenna demonstrates our commitment to providing our customers with AI solutions that help them to improve the quality of care. With its proven ability to help radiologists to identify pathologies quickly, but also to highlight those that require the most urgent care, CINA Head is exactly the kind of innovative solution that we want to offer clinicians.”
Cyril Di Grandi, co-founder and CEO, Avicenna.AI, said, “Our partnership with a medical imaging modality leader like Canon Medical Systems is a testament to the excellent accuracy, sensitivity and specificity data that has been gathered during our validation phase. We look forward to working with our new partner to bring the benefits of our AI-powered stroke triage solution to the emergency room and beyond.”
About Canon Medical Systems Corporation
Canon Medical offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound, Vascular and MR, as well as a full suite of Healthcare IT solutions, across the globe. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features.
At Canon Medical, we work hand in hand with our partners – our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life. For more information, visit the Canon Medical website: https://global.medical.canon.

12/11/2020
Avicenna.AI secures FDA clearance for its CINA neurovascular imaging Tool

CINA supports emergency room triage for intracranial hemorrhages and large vessel occlusions.
Paris, FRANCE – July 14, 2020 – Medical imaging AI specialist Avicenna.AI today announced it has received 510(k) clearance from the US Food and Drug Administration (FDA) for its CINA triage AI solution for neurovascular emergencies. The FDA’s decision covers CINA’s automatic detection capabilities for both intracranial hemorrhage (ICH) and large vessel occlusion (LVO) from CT-scan imaging.
Stroke is a leading cause of death in the US, with more than 795,000 strokes resulting in more than 100,000 deaths each year. It is estimated that up to a third of the most common type of stroke are caused by LVO, when a clot blocks the circulation of the blood in the brain. Around 1 in 10 strokes are thought to be caused by ICH, or bleeding that occurs inside the skull. Using a combination of deep learning and machine learning technologies, CINA automatically detects and prioritizes acute ICH and LVO cases within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow.
Dr. Peter Chang, radiologist and co-founder of Avicenna.AI, said, “When dealing with a stroke, time is of the essence and being able to prioritize effectively is critical to saving lives and improving outcomes. Not only does CINA helps radiologists to identify pathologies quickly, but also to highlight those that require the most urgent care.”
CINA’s ICH detection capability was validated using data from 814 cases conducted at more than 250 imaging centers across the United States, with 96% accuracy, 91.4% sensitivity, and 97.5% specificity. The product’s LVO detection capability was validated based on 476 cases, with 97.7% accuracy 97.9% sensitivity, and 97.6% specificity.
Cyril Di Grandi, co-founder, and CEO of Avicenna.AI, said, “We’re excited to have received FDA clearance for CINA and we are looking forward to working with emergency departments and stroke centers across the United States to help improve detection, decision-making and patient outcomes. As a triage AI tool that identifies multiple pathologies, we believe that CINA delivers more value than AI tools or algorithms that only target a single condition.”
CINA is the first in a family of AI tools for emergency radiology being developed by Avicenna.AI. Subsequent products spanning the trauma and vascular fields are expected to be unveiled in the next 12 months.

14/07/2020
Avicenna.AI completes its first round of financing for 2.7 million dollars

Marseille, February 6th, 2020 – Avicenna.AI, a company specialized in the development of software for the detection of emergency pathologies in CT scanners, announces the completion of its first capital increase with Innovacom and CEMAG Invest for an amount of almost 3 million dollars. This is one of the largest fund raising in France this year in the medical imaging field.
Avicenna.AI develops new generation of algorithms dedicated to the detection of life threatening lesions. For detecting these pathologies affecting a large number of patients worldwide, Avicenna.AI offers healthcare professionals new tools of unrivalled effectiveness, enabling them to improve patient care, in particular by helping specialists to identify faster the patients who need to be treated as a priority in an emergency context.
Avicenna.AI was created by gathering experts in medical software and radiologists to offer solutions that are in line with clinical routines. This partnership has led to important collaborations with hospitals, research laboratories and one of the largest tele-radiology groups in the world, providing the necessary confidence to the major manufacturers in the field to integrate our solution into their offer.
“Avicenna.AI’s ambition is to become a leader in the diagnostic assistance for radiologists. By concentrating our efforts on emergency imaging, we will enable a reduction in interpretation time, faster patient care and improved diagnostic quality in a clinical context that everyone knows is tense. With this funding, Avicenna.ai will be able to commercially develop its product in Europe and register it in the United States, and continue its R&D program to reliably improve the radiologist’s routine,” said Cyril DI GRANDI, co-founder and president of Avicenna.ai.
“Our solution seamlessly integrates into the clinical routine and requires no additional interfaces for the radiologist, who is already overwhelmed by a multiplicity of them, whether dictating the report or viewing images. In addition, our software offers the dual advantage of being totally secure and offering unequalled performance in the detection of pathologies”, explains Peter CHANG, MD, co-founder and leader opinion in artificial intelligence.
About Innovacom
Since 1988, Innovacom has invested closed to one billion euros, supported more than 300 digital startups, participated in more than 20 IPOs and completed 150 industrial disposals.
Innovacom has contributed to several recent successes in various sectors: electric vehicles (G²mobility), ad tech (Videoplazza), medical imaging (Olea Medical), digital customer relations (Dimelo), connectivity in trains (21Net Ltd) or components for smartphones with the Heptagon unicorn.
Innovacom currently supports high-potential companies such as Aryballe Technologies, CAILabs, Cozy Cloud, Exagan, Feeligreen, Intersec, Iten, Kolibree, MicroEJ, Matrixx Software, Robart Gmbh and Scintil Photonics.
Its recent association with the Turenne Group, one of France’s leading independent private equity firms, has given rise to a €1 billion platform under management. Present in Paris and Marseille, Innovacom is a company approved by the Autorité des Marchés Financiers.
About Cemag Invest
Cemag Invest is a family office dedicated to healthcare and technology, with a focus on adding value to patients. Cemag Invest has notably invested in Wandercraft, Diabeloop, and alongside innovacom in Aryballe Technologies.

07/02/2020